Previous 10 | Next 10 |
Nurix Therapeutics (NRIX): FQ1 GAAP EPS of -$0.63 misses by $0.20.Revenue of $5.01M (+75.2% Y/Y) misses by $2.93M.As of February 28, 2021, Nurix had cash, equivalents and investments of $380.3 million compared to $372.0 million as of November 30, 2020.Press Release For further details see: ...
On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after successful $150 million follow-on offering in March 2021 SAN FRANCISC...
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate in a...
Nurix Therapeutics (NRIX) started off last week on a high note, striking a research deal on Tuesday with Alex’s Lemonade Stand Foundation to develop a drug to potentially treat aggressive childhood cancers.The stock reached its weekly high that day of $47.20.But by Friday, shares ...
Nurix Therapeutics ([[NRIX]] +3.9%) announces that it is part of a collaboration sponsored by Alex’s Lemonade Stand Foundation ((ALSF)), a leading funder of pediatric cancer research, to develop a drug to potentially treat aggressive childhood cancers including neuroblastoma and m...
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex’s Lemonade Stand Foundation-funded $18.5 million Crazy 8 Initiative SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) -- Nurix...
Instil Bio has filed terms for its $250 million IPO. The firm is advancing autologous TIL treatment candidates for melanoma and other solid tumor cancers. TIL has produced intriguing early efficacy results but the IPO is priced far above the normal life science IPO range, so I'll ...
CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cells Preclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 blockade SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics,...
Kymera Therapeutics is a next-generation targeted protein degradation company working to drug the undruggable genome. The company's platform has attracted three biopharma deals worth more than $3B. Kymera is filing three investigational drug applications in 2021 that might create ...
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public offer...
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
2024-07-12 17:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for NRIX on July 12, 2024 03:19PM ET. The previous analyst recommendation was Outperform. NRIX was trading at $23.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa,...
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., pr...